Bayer AG

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bayer AG engages in the business of life science fields of healthcare and nutrition. It operates through the following segments: Crop Science, Pharmaceuticals, and Consumer Health. The Crop Science segment includes developing, producing, and marketing products in seeds and plant traits, crop protection, digital solutions, and customer services to promote sustainable agriculture. The Pharmaceuticals segment is involved in prescription products especially for cardiology and women’s health; specialty therapeutics in the areas of oncology, hematology, ophthalmology, and cell and gene therapy; diagnostic imaging equipment; and necessary contrast agents. The Consumer Health segment focuses on non-prescription products in the dermatology, nutritional supplements, digestive health, allergy, cough and cold, and pain and cardiovascular risk prevention categories. The company was founded by Friedrich Bayer and Johann Friedrich Westkott on August 1, 1863 and is headquartered in Leverkusen, Germany.

Bayer reported second quarter results and while the results were nothing to get excited about, it was at least not a disappointment. While the Crop Sciences segment is still struggling, Pharmaceuticals and Consumer Health are growing at a solid pace (at least FX adjusted). While the major risks for the business – high debt levels and litigations – remain, the transformation towards a leaner business structure as well as growth and innovation also takes place.

Bayer: Risks Remain While Business Is Stabilizing

I recommend keeping a close eye on Bayer's performance and potential investment opportunities. I have been cautious about Bayer since last article, which discussed the company cutting its dividend. Bayer's stock has since rebounded, with potential for further growth due to positive developments in its pharmaceutical and agricultural divisions.

Bayer: Why I'm Careful, But Rate It Buy

Bayer's (BAYRY) second-quarter earnings match the consensus estimate. Sales gain from the Pharmaceutical business' strong performance.

Bayer (BAYRY) Q2 Earnings In Line, Nubeqa, Kerendia Boost Sales

ORLANDO, Fla.--(BUSINESS WIRE)--As Radiology administrators from around the US gather for the annual AHRA (American Healthcare Radiology Administrators) conference, Bayer is announcing an exploratory collaboration with Alara Imaging, Inc. "Radiation doses from computed tomography (CT) scans on patients are highly variable across patients and hospitals throughout the United States and other nations.1 Radiation doses that are beyond what are necessary to perform adequate CT scans represents a mod.

Bayer and Alara Imaging Announce Collaboration

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that FINEARTS-HF met its primary endpoint,1 achieving a statistically significant reduction of the composite of cardiovascular death and total (first and recurrent) heart failure (HF) events, defined as hospitalizations for HF or urgent HF visits. The randomized, double-blind, placebo-controlled, parallel-group, multi-center phase III cardiovascular outcomes study evaluated the efficacy and safety of KERENDIA® (finerenone) for investigation.

Bayer Announces Primary Endpoint Achieved in Phase III FINEARTS-HF Cardiovascular Outcomes Study Investigating KERENDIA® (finerenone) in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction

BERLIN--(BUSINESS WIRE)--Bayer today announced that a New Drug Application (NDA) for the investigational compound elinzanetant has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe vasomotor symptoms (VMS, also known as hot flashes) associated with menopause. The submission is based on the positive results from the Phase III OASIS 1, 2 and 3 studies. “Half of the world's population will experience menopause, with 27 million women in the U.S. c.

Bayer Submits New Drug Application to U.S. FDA for Elinzanetant for the Treatment of Moderate to Severe Vasomotor Symptoms Associated With Menopause

Monsanto will pay $160 million to settle a lawsuit by the city of Seattle that accused the unit of Germany's Bayer of polluting the city's drainage system and the local Lower Duwamish River with toxic chemicals known as PCBs.

Bayer's Monsanto to pay $160 mln to resolve Seattle's PCB contamination lawsuit

An Australian judge said on Thursday it was not proven that an ingredient in Bayer's Roundup weedkiller increases the risk of cancer in users.

Australian judge dismisses lawsuit claiming Bayer's Roundup weedkiller causes cancer

An Australian judge will rule on Thursday on whether Bayer's Roundup weedkiller can cause a type of blood cancer, a closely watched decision that follows some jury verdicts in similar U.S. cases that have found for the plaintiffs.

Australian court to rule on whether Bayer weedkiller can cause blood cancer

Bayer (BAYRY) meets the primary goal in the phase III study evaluating the darolutamide/ADT combo without docetaxel in metastatic hormone-sensitive prostate cancer patients.

Bayer (BAYRY) Meets Primary Goal in Nubeqa Expanded-Use Study

Bayer said on Wednesday its drug candidate darolutamide was shown to slow the progression of certain types of prostate cancer in a late-stage trial.

Bayer says darolutamide shown to slow prostate cancer progression

WHIPPANY, N.J.--(BUSINESS WIRE)--The Phase III ARANOTE trial, investigating NUBEQA® (darolutamide) plus androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC), has met its primary endpoint of radiological progression-free survival (rPFS). NUBEQA plus ADT demonstrated a statistically significant and clinically meaningful increase in rPFS compared to placebo plus ADT. Results were consistent with NUBEQA's established safety profile with no new sign.

Bayer announces positive topline results for NUBEQA® (darolutamide) from Phase III trial in men with metastatic hormone-sensitive prostate cancer (mHSPC)

Kroger

CINCINNATI--(BUSINESS WIRE)--Bayer and Kroger joined forces with country music star Luke Bryan and Feeding America to bring healthy food to more families who need it. According to Feeding America's latest data, more than 44 million people in the United States are food insecure1, including a nearly 30% increase – more than 10 million – compared to the previous year. Building on the successful launch of the "Take Care, Now” campaign in 2023, the collaborators are announcing their efforts to again.

Bayer and Kroger Team Up with Luke Bryan and Feeding America to Improve Access to Nutritious Food

NATIONAL HARBOR, Md.--(BUSINESS WIRE)--As experts from around the globe gather at the annual Society for Informatics in Medicine (SIIM) conference, Bayer and Rad AI are announcing a collaboration to bring Rad AI's cutting edge AI radiology operational solutions to Calantic ™ Digital Solution customers. Rad AI's radiology speech recognition reporting solution, AI-driven patient follow-up management, and automated radiology impression generation technologies complement Bayer's Calantic™ Digital S.

Bayer and Rad AI Announce Collaboration agreement

Bayer's (BAYRY) wholly owned and independently operating subsidiary AskBio started recruitment in the phase II study for Parkinson's disease.

Bayer's (BAYRY) AskBio Advances Parkinson Disease Study

A top Bayer pharmaceutical executive said on Wednesday his group will continue slashing managerial jobs this year, planning cuts in Germany, Japan, the United Kingdom, Belgium and the Netherlands as part of the company's internal reorganization.

Bayer's pharmaceutical unit plans more managerial cuts in Europe, Asia

WAGENINGEN, Netherlands--(BUSINESS WIRE)--Bayer and Solynta have reached an agreement to collaborate on the commercialization and distribution of true potato seeds in Kenyan and Indian markets. This partnership marks Bayer's entry into the 20 million hectare global potato market and its first collaboration with Solynta, a Dutch company developing robust hybrid potato varieties. The collaboration will center around Solynta's expert knowledge of potato breeding with the development of new robust.

Bayer and Solynta Collaborate to Advance True Potato Seed in Smallholder Markets

Bayer's crop science division is increasingly turning to artificial intelligence in its battle against crop killing weeds, the company told Reuters.

Bayer looks to AI to combat herbicide resistance faster

A Pennsylvania judge on Tuesday slashed a $2.25 billion U.S. verdict against Bayer to $400 million for a Pennsylvania man who said he developed cancer from exposure to the company's Roundup weedkiller.

Judge cuts Bayer $2.25 billion Roundup verdict to $400 million

JEFFERSON CITY, Mo. — After failing in several U.S. states this year, global chemical manufacturer Bayer said Tuesday that it plans to amplify efforts to create a legal shield against a proliferation of lawsuits alleging it failed to warn that its popular weedkiller could cause cancer.

Bayer, maker of Roundup weedkiller, steps up fight against cancer-related lawsuits

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer will present new data across its oncology portfolio at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago, from May 31 – June 4, 2024. The breadth of new data in different tumor types underscores Bayer's ambition to deliver innovative and effective oncological therapies in areas with the highest unmet medical needs. Prostate cancer is a key focus for Bayer Oncology, with data to be presented on NUBEQA® (darolu.

Bayer presents latest data from oncology portfolio at 2024 ASCO Annual Meeting

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy. The investigational candidate, labeled with actinium-225 and comprising a novel PSMA (prostate-specific membrane antigen) -targeting small molecule with a customized albumin-binding moiety, is designed to potentially improve therapeutic efficacy and reduce side effects in normal organs such as salivary gl.

Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer AG [BAYZF] Q1 2024 Earnings Conference Call May 14, 2024 8:00 AM ET Company Participants Bill Anderson - Chairman & CEO Wolfgang Nickl - CFO Julio Triana - President, Consumer Health Division Stefan Oelrich - President, Pharmaceuticals Division Rodrigo Santos - President, Crop Science Division Jost Reinhard - IR Conference Call Participants Emily Field - Barclays Vincent Andrews - Morgan Stanley Peter Verdult - Citibank Richard Vosser - J.P. Morgan Joel Jackson - BMO Capital Markets Florent Cespedes - Bernstein Sachin Jain - Bank of America Jost Reinhard Good afternoon, good morning to everybody.

Bayer AG (BAYZF) Q1 2024 Earnings Call Transcript

Bayer's (BAYRY) Q1 earnings and sales decline year over year due to a fall in volumes for non-glyphosate-based herbicides and lower prices for glyphosate-based products in the Crop Science division.

Bayer (BAYRY) Q1 Earnings Fall Y/Y on Lower Product Sales

Bayer on Tuesday reported a 1.3% decline in adjusted earnings in the first quarter, beating analysts' forecasts on better-than-expected performance at its prescription drugs and agriculture divisions.

News for Bayer AG Stock (BAYRY)